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to the extremes of ranges, and start date for length of survival: method 
1. progression after second line therapy or three weeks post last dose of 
chemo for control group and start date of erlotinib for treatment group; 
method 2. last date of second line therapy for both groups. 
75 control and 70 erlotinib patients were included in the analysis. 
Results are presented in the table. The Incremental Cost-Effectiveness 
Ratio (ICER) was $28,516 per life-year-gained under method 1, and 
$17,632 under method 2. The erlotinib group had similar one year OS 
compared to literature (36 vs. 31%).
Method 1: Parameter Controls (N=75) Erlotinib (N=70)
Area under curve (months) 3.86 7.91
p-value (log-rank test) <0.001
Median Survival months (95% CI) 2.56 (2.04-4.8) 4.73 (2.89-14.7)
1-year OS % (95% CI) 0.04 (0.01-0.13) 0.36 (0.24-0.53)
Mean drug cost $CDN/patient (range) 7,560 (1,445-26,710) 17,184 (2,660-58,539)
ICER $28,516/LYG
Method 2: Parameter
Area under curve 5.35 11.90
p-value (log-rank test) <0.001
Median Survival months (95% CI) 3.35 (2.53-6.38) 8.61 (7.56-19.99)
1-year OS % (95% CI) 0.11 (0.06-0.21) 0.45 (0.34-0.60)
ICER $17,632/LYG
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Background: Epidermal Growth Factor Receptor tyrosine kinase 
Inhibitors (EGFRTKI) have proven selective efﬁcacy in advanced 
NSCLC where potential predictors of response have been studied. 
Their role in early stage NSCLC has not been established.
Purpose: Using pharmacodynamic sampling pre- and post-therapy 
with geﬁtinib, 1) to assess the impact of geﬁtinib on EGFR intracellular 
signaling pathways; and 2) to assess response and toxicity rates after 
preoperative geﬁtinib (Iressa, AstraZeneca)
Methods: Stage I NSCLC patients received geﬁtinib (Iressa, 250 
mg/day) for 28 days followed by mediastinoscopy and surgical resec-
tion in a single arm open label study. Tumor response was evaluated by 
RECIST. Pre-treatment (snap frozen, core needle biopsy) and post-
operative (snap frozen and formalin ﬁxed, surgical specimen) tumor 
samples were obtained. Mutation analysis of EGFR exons 19 and 21 
was performed by PCR fragment length analysis and direct sequencing. 
EGFR, its phospho-isoforms and intracellular signaling pathways were 
analyzed by immunohistochemistry 
Results: Thirty-four patients have completed treatment. Mean fol-
low-up is 4.7 months (2.3-11.6). Sixty-ﬁve percent of cases were 
adenocarcinomas, 21% squamous cell, 12% pure BAC, and 3% large 
cell carcinoma. Fifty percent were active smokers, 38% former smok-
ers and 12% never smoked. No unexpected toxicities during geﬁtinib 
treatment were seen. Five patients had serious adverse events within 
30 days post-surgery (2 pulmonary infections, 2 prolonged air leaks, 1 
pulmonary embolism). Four (12%) patients had exon 19 deletions and 
two (6%) had exon 21 point mutations. Two pts with exon 19 deletions 
had a partial response (PR) to treatment, the others stable disease (SD). 
One pt with exon 21 point mutation had a PR, the other SD. In patients 
without mutation, 1 had a PR, 22 SD, and 3 PD on therapy. The overall 
response rate was 11.7% in the sample. No differences in mutations 
were detected comparing pre- and post-treatment specimens. 
By univariate analyses (Fisher’s Exact Test and t-Test), presence of ﬁ-
brosis in surgically resected specimens was associated with any EGFR 
mutation (p=0.002) and exon 19 deletion alone (p=0.008). Female gen-
der (p=0.007), never-smoking status (0.029), BAC (p=0.009), EGFR 
mutation (p=0.002), and exon 19 deletion (p=0.023) were associated 
with a reduction in maximum tumor diameter, but only any EGFR mu-
tation (p=0.016) was associated with RECIST response. In multivariate 
analysis, the only variable associated with tumor reduction, RECIST re-
sponse and ﬁbrosis was the presence of any EGFR mutation, (p=0.016). 
Preliminary analysis suggests non responders are not experiencing 
complete EGFR inhibition in vivo. Additional measures associated with 
response are under assessment. 
Conclusions: Geﬁtinib can be administered safely preoperatively in 
early NSCLC. EGFR mutation analysis is feasible on percutaneous 
biopsies. Short-term EGFRTKI treatment does not result on changes in 
mutation proﬁle. Comparison of pre- and post-therapy tumor samples 
may allow additional understanding of EGFR TKI resistance and facili-
tate patient selection.
Overall, response rates and predictors of response in early stage 
NSCLC are not different from advanced disease.
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Background: The phase III randomised BR.21 study demonstrated 
that in patients with relapsed advanced NSCLC, erlotinib (Tarceva®) 
improved survival and prolonged time to symptom deterioration 
compared with placebo (Shepherd et al. NEJM 2005;353:123-132). 
Erlotinib was well tolerated, with rash and diarrhoea the most com-
mon adverse events (AEs), both being generally mild to moderate in 
severity. The global, open-label TRUST study was initiated to provide 
erlotinib access to patients with advanced NSCLC. Data are reported 
here for the E/SE subgroup.
Methods: Eligible patients with stage IIIB/IV NSCLC had failed previ-
ous chemotherapy for advanced disease (≤2 prior regimens) or were 
unsuitable for chemotherapy. Erlotinib was administered orally 150mg/
